A5100735031- CAR-T cell therapy research
- Nanoparticle-Based Drug Delivery
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Nanoplatforms for cancer theranostics
- RNA Interference and Gene Delivery
- Advancements in Semiconductor Devices and Circuit Design
- Nanowire Synthesis and Applications
- Cancer Immunotherapy and Biomarkers
- Virus-based gene therapy research
- Acute Lymphoblastic Leukemia research
- Multiple Myeloma Research and Treatments
- Integrated Circuits and Semiconductor Failure Analysis
- Viral Infectious Diseases and Gene Expression in Insects
- Biopolymer Synthesis and Applications
- Biosimilars and Bioanalytical Methods
- Cancer Treatment and Pharmacology
- T-cell and B-cell Immunology
- Hematopoietic Stem Cell Transplantation
- Extracellular vesicles in disease
- Silicon Carbide Semiconductor Technologies
- Advanced biosensing and bioanalysis techniques
- HER2/EGFR in Cancer Research
- Monoclonal and Polyclonal Antibodies Research
- Cancer therapeutics and mechanisms
East China Normal University
2015-2024
Nanchang University
2024
Zhejiang University
2012-2023
Sun Yat-sen University
2022-2023
First Hospital of China Medical University
2022-2023
Rush University Medical Center
2022-2023
University of Hong Kong
2022-2023
Beijing Tongren Hospital
2023
Shanghai Medical College of Fudan University
2023
Hong Kong University of Science and Technology
2022-2023
Glioblastoma is one of the most challenging and intractable tumors with difficult treatment poor prognosis. Unsatisfactory traditional systemic chemotherapies for glioblastoma are mainly attributed to insufficient nonspecific drug delivery into brain as well incomplete release at tumor sites. Inspired by facts that angiopep-2 peptide an acknowledged dual-targeting moiety tumor-targeting high-intensity focused ultrasound (HIFU) ideal trigger ultrahigh energy millimeter-sized focus ability, in...
Abstract Foxp3 + regulatory T cells (Tregs) can inhibit immune responses and maintain tolerance by secreting immunosuppressive TGF-β1 IL-10. However, the efficiency of Tregs become major obstacle to their use for immunotherapy. In this study, we investigated relevance C-type lectin receptor CD69 suppressive function. Compared CD4 − (CD69 Tregs), Tregs) displayed stronger ability tolerance. expressed higher levels suppression-associated markers such as CTLA-4, ICOS, CD38 GITR, secreted IL-10...
Previous studies on the treatment of hepatic cirrhosis have been focusing how to inhibit liver fibrosis, while ignoring inflammation, a key and underlying factor that promotes cirrhosis. High mobility group box-1 (HMGB1) protein, pro-inflammatory fibroblast chemokine, can promote proliferation stellate cells (HSCs) development inflammation playing role in formation. In this study, we prepared pPB peptide (C*SRNLIDC*)-modified HMGB1-siRNA-loaded stable nucleic acid lipid nanoparticles...
Abstract Few prospective studies have examined posttransplant chimeric antigen receptor (CAR) T cell infusion as candidates for front‐line consolidation therapy high‐risk multiple myeloma (MM) patients. This single‐arm exploratory clinical trial is the first to evaluate safety and efficacy of sequential anti‐CD19 anti‐BCMA CAR‐T infusion, followed by lenalidomide maintenance after autologous stem transplantation (ASCT), in 10 newly diagnosed (NDMM) The treatment was generally well tolerated,...
The conventional chemotherapeutics could not be traced in vivo and provide timely feedback on the clinical effectiveness of drugs.Methods: In this study, a tumor-penetrating peptide RGERPPR (RGE) modified, Gd-DTPA conjugated, doxorubicin (DOX) loaded Fe3O4@SiO2@mSiO2 nanoparticle drug delivery system (Fe3O4@SiO2@mSiO2/DOX-(Gd-DTPA)-PEG-RGE NPs) was prepared for tumor theranostics.Results: Fe3O4@SiO2@mSiO2/DOX-(Gd-DTPA)-PEG-RGE NPs showed z-average hydrodynamic diameter about 90 nm,...
We have previously demonstrated that exosomes from dendritic cells (DCs) secreting TGF‐β1 (sTGF‐β1‐EXOs) delay the development of murine inflammatory bowel disease (IBD). In this study, we isolated DCs expressing membrane‐associated (mTGF‐β1‐EXOs) and found mTGF‐β1‐EXOs had more potent immunosuppressive activity than sTGF‐β1‐EXOs in vitro. Treatment mice with inhibited progression myelin oligodendrocyte glycoprotein (MOG) peptide‐induced EAE even after onset. also impaired Ag‐specific Th1...
Chimeric antigen receptor T-cell (CAR-T) therapy demonstrates impressive efficacy in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). However, CAR-T therapy-related severe cytokine release syndrome and neurological toxicity limit its clinical application R/R DLBCL patients with high tumor burden. Here, we conducted a phase II trial testing the toxicities of non-Hodgkin (NCT03196830). Among enrolled patients, 10 burden were analyzed. Before therapy, 4 treated intensive...
T cells expressing a chimeric antigen receptor (CAR) engineered to target CD19 can treat leukemia effectively but also increase the risk of complications such as cytokine release syndrome (CRS) and CAR cell related encephalopathy (CRES) driven by interleukin-6 (IL-6). Here, we investigated whether IL-6 knockdown in CART-19 reduce secretion from monocytes, which may adverse events.Supernatants cocultures regular B lymphoma were added monocytes vitro, levels monocyte supernatants measured 24 h...
The application of nano drug delivery systems (NDDSs) may enhance the effectiveness chemotherapeutic drugs in vivo. However, short blood circulation time and poor release profile vivo are still two problems with them. Herein, by using red cell membrane (RBCm) wrapping pH sensitive technology, we prepared RBCm wrapped poly(l-γ-glutamylcarbocistein)-paclitaxel (PGSC-PTX) nanoparticles (PGSC-PTX@RBCm NPs), to prolong PTX timely adequately acidic tumor environment. PGSC-PTX NPs PGSC-PTX@RBCm...
Hepatic fibrosis is a necessary process in the development of liver diseases such as hepatic cirrhosis and its complications, which has become serious threat to human health. Currently, antifibrotic drug treatment ineffective, one reason should be lack targeting ability. In this report, polypeptide pPB-modified stable nucleic acid lipid nanoparticles (pPB-SNALPs) were prepared selectively deliver siRNAs against heat shock protein 47 for targeted therapy fibrosis. First, siRNA sequences with...
Abstract The low rate of durable response against relapsed and/or refractory multiple myeloma (RRMM) in recent studies indicates that chimeric antigen receptor T‐cell (CART) treatment is yet to be optimized. This study aims investigate the safety and efficacy sequential infusion CD19‐CART B‐cell maturation (BCMA)‐CARTs for RRMM with a similar 3 + dose escalation combined toxicity sentinel design. We enrolled 10 patients, among whom 7 received autologous allogeneic infusion. median follow‐up...
Background The use of T cells expressing chimeric antigen receptor (CAR T) engineered to target CD19 constitutes breakthrough treatment for relapsed or refractory B cell non-Hodgkin lymphoma (R/R B-NHL). Despite improved outcomes, high relapse rate remains a challenge overcome. Here, we report the clinical results and pharmacokinetics bispecific CD19/22 CAR in patients with R/R B-NHL. Methods We performed prospective, single-arm study analyzed safety efficacy investigated kinetic profiles...
The activation of chimeric antigen receptor (CAR)‑T cells can lead to persistently high levels programmed cell death 1 (PD‑1) and eventually causes the exhaustion T cells. effectiveness CAR‑T targeting C‑type lectin‑like molecule‑1 (CLL‑1) combined with PD‑1 silencing therapy for acute myeloid leukemia (AML) was evaluated in present study. CLL‑1 primary AML bone marrow samples examined using flow cytometric analysis. We designed a CAR‑T, containing CLL‑1‑specific single‑chain variable...